Search Results - "Demas, Diane M"

Glutamine Metabolism Drives Growth in Advanced Hormone Receptor Positive Breast Cancer by Demas, Diane M, Demo, Susan, Fallah, Yassi, Clarke, Robert, Nephew, Kenneth P, Althouse, Sandra, Sandusky, George, He, Wei, Shajahan-Haq, Ayesha N

“…Dependence on the glutamine pathway is increased in advanced breast cancer cell models and tumors regardless of hormone receptor status or function. While 70%…”
Get full text

Targeting WEE1 Inhibits Growth of Breast Cancer Cells That Are Resistant to Endocrine Therapy and CDK4/6 Inhibitors by Fallah, Yassi, Demas, Diane M., Jin, Lu, He, Wei, Shajahan-Haq, Ayesha N.

“…Despite the success of antiestrogens in extending overall survival of patients with estrogen receptor positive (ER+) breast tumors, resistance to these…”
Get full text

MYC regulates the unfolded protein response and glucose and glutamine uptake in endocrine resistant breast cancer by Shajahan-Haq, Ayesha N, Cook, Katherine L, Schwartz-Roberts, Jessica L, Eltayeb, Ahreej E, Demas, Diane M, Warri, Anni M, Facey, Caroline O B, Hilakivi-Clarke, Leena A, Clarke, Robert

“…About 70% of all breast cancers are estrogen receptor alpha positive (ER+) and are treated with antiestrogens. However, 50% of ER + tumors develop resistance…”
Get full text

Modeling breast cancer proliferation, drug synergies, and alternating therapies by He, Wei, Demas, Diane M., Shajahan-Haq, Ayesha N., Baumann, William T.

“…Estrogen receptor positive (ER+) breast cancer is responsive to a number of targeted therapies used clinically. Unfortunately, the continuous application of…”
Get full text

Mathematical modelling of breast cancer cells in response to endocrine therapy and Cdk4/6 inhibition by He, Wei, Demas, Diane M, Conde, Isabel P, Shajahan-Haq, Ayesha N, Baumann, William T

“…Oestrogen receptor (ER)-positive breast cancer is responsive to a number of targeted therapies used clinically. Unfortunately, the continuous application of…”
Get full text

Resistance to abemaciclib is associated with increased metastatic potential and lysosomal protein deregulation in breast cancer cells by Scheidemann, Erin R., Demas, Diane M., Hou, Chunyan, Ma, Junfeng, He, Wei, Sharma, Gaurav, Schultz, Eric, Weilbaecher, Katherine N., Shajahan‐Haq, Ayesha N.

“…Cyclin dependent kinase 4 and 6 inhibitors such as abemaciclib are routinely used to treat metastatic estrogen receptor positive (ER+) breast cancer. However,…”
Get full text

Abstract 4758: Targeting cellular pH as a novel therapeutic strategy in CDK4/6 inhibitor resistant breast cancer by Scheidemann, Erin R., Demas, Diane M., Shajahan-Haq, Ayesha N.

“…Abstract Cyclin dependent kinase 4 and 6 inhibitors (CDK4/6i) are part of standard of care therapy in combination with antiestrogens for the treatment of…”
Get full text

Abstract 674: Predicting cellular response to therapy in breast cancer using mathematical modeling by He, Wei, Demas, Diane M., Conde, Isabel, Fallah, Yassi, Baumann, William T., Shajahan-Haq, Ayesha N.

“…Abstract About 70% of all breast cancer tumors are estrogen receptor positive (ER+) and are treated with antiestrogen therapies. While the inevitability of…”
Get full text

9354 Combination Of Novel Ruthenium-based Small Molecule Bold-100 And Capecitabine Is Effective In Inhibiting Growth Of Estrogen Receptor Positive Metastatic Breast Cancer by Scheidemann, Erin R, Demas, Diane M, Ashai, Nadia, Shajahan-Haq, Ayesha N

“…Abstract Disclosure: E.R. Scheidemann: None. D.M. Demas: None. N. Ashai: None. A.N. Shajahan-Haq: None. The most common breast cancer subtype in both women and…”
Get full text

9354 Combination Of Novel Ruthenium-Based Small Molecule Bold-100 And Capecitabine Is Effective In Inhibiting Growth Of Estrogen Receptor Positive Metastatic Breast Cancer by Scheidemann, Erin R, Demas, Diane M, Ashai, Nadia, Shajahan-Haq, Ayesha N

“…Abstract Disclosure: E.R. Scheidemann: None. D.M. Demas: None. N. Ashai: None. A.N. Shajahan-Haq: None. The most common breast cancer subtype in both women and…”
Get full text

Abstract 1786: SM-88, D/L-alpha-metyrosine, is a novel anti-cancer agent in estrogen receptor positive breast cancer by Demas, Diane M., Collins, Julie, Shajahan-Haq, Ayesha N.

“…Abstract Breast cancer is the second most common cause of death from cancer in women in the United States after lung cancer. Estrogen receptor positive (ER+)…”
Get full text

Abstract 430: Combination of CB-839 and everolimus is effective in inhibiting growth of endocrine resistant breast cancer in vivo by Fallah, Yassi, Demas, Diane M., Demo, Susan, Shajahan-Haq, Ayesha N.

“…Abstract About 70% of all breast cancers are estrogen receptor alpha positive (ER+). Anti-hormone therapy such as antiestrogens are often used to treat ER+…”
Get full text

Abstract 1258: The unfolded protein response may contribute to racial disparity in endocrine responsiveness in breast cancer by Eltayeb, Ahreej E., Demas, Diane M., Clarke, Robert, Shajahan-Haq, Ayesha N.

“…Abstract About 70% of all breast cancers are estrogen receptor alpha positive (ER+) and depend on estrogen to grow and proliferate. Anti-hormone therapy such…”
Get full text

Abstract B1-23: Early growth response (EGR1) is a critical regulator of cellular metabolism and predicts increased responsiveness to antiestrogens in breast cancer by Shajahan-Haq, Ayesha N., Jin, Lu, Cheema, Amrita K., Boca, Simina M., Gusev, Yuriy, Bhuvaneshwar, Krithika, Demas, Diane M., Ressom, Habtom, Michalek, Ryan, Chen, Xi, Xuan, Jianhua, Madhavan, Subha, Clarke, Robert

“…Abstract Breast cancer is the most commonly diagnosed cancer in women and about 1 million new cases per year are diagnosed worldwide. About 70% of all breast…”
Get full text

Abstract 679: Glutamine metabolism in MYC-driven antiestrogen resistant breast cancer cells confers metabolic flexibility through the unfolded protein response by Shajahan-Haq, Ayesha N., Cook, Katherine L., Schwartz-Roberts, Jessica L., Eltayeb, Ahreej E., Demas, Diane M., Warri, Anni M., Hilakivi-Clarke, Leena A., Clarke, Robert

“…Abstract Antiestrogens are used to treat estrogen receptor positive (ER+) breast tumors that constitute 70% of all breast cancer cases. Unfortunately, acquired…”
Get full text

Abstract 5397: MYC-driven glutamine metabolism promotes antiestrogen resistance in breast cancer by Shajahan, Ayesha N., Cook, Katherine L., Schwartz-Roberts, Jessica L., Eltayeb, Ahreej E., Demas, Diane M., Warri, Anni, Hilakivi-Clarke, Leena, Metallo, Steven, Clarke, Robert

“…Abstract About 70% of newly diagnosed cases of invasive breast cancer in the U.S. will be estrogen receptor alpha positive (ER+). Endocrine therapy is the…”
Get full text